U.S. flag

An official website of the Department of Health & Human Services

AHRQ: Agency for Healthcare Research and Quality

Substance Use Tools & Resources   

Read the Guide

This collection of tools and resources is for providers, staff, and patients who offer or use services to address substance use, and other interested stakeholders. This collection was originally established following an environmental scan on implementing medication-assisted treatment (MAT) for opioid use disorder (OUD) in rural primary care. (See PDFs of Volume 1 (PDF - 609 KB) and Volume 2 (PDF - 1.3 MB) of that scan). Items have been continuously added to this collection since then, and the collection has expanded to cover substance use more broadly, rather than just MAT for OUD.

Displaying 11 - 20 of 100

Fentanyl Statistics 2025: Up-to-Date Facts on Abuse and Overdose

This article utilizes the most up-to-date statistics available to provide an accurate picture of the fentanyl crisis in 2024. For some statistics, the most up-to-date information will be cut off in 2021.
Format
Web Page
Audience
Policymakers and Payers
States
Communities
Source
Addiction Group
Year
Resource Type
Web Page

Integrating Harm Reduction into Health Care Facilities Serving Medicaid Members

This webinar, hosted by the Center for Health Care Strategies (CHCS), explored how providers and administrators in health care settings serving Medicaid members can integrate harm reduction strategies into their practices, supported by creative and sustainable financing mechanisms. It featured a panel discussion with harm reduction leaders experienced at the provider, state, and national levels.
Format
Webinar/Video
Audience
Medical Providers
Behavioral Health Providers
Other Team Members
Source
Center for Health Care Strategies
Year
Resource Type
Web Page

Quick Guide to Over-the-Counter Naloxone (PDF - 519 KB KB)

This guide highlights naloxone, a lifesaving medication that reverses an opioid overdose. It includes information on when to carry naloxone, how to recognize an overdose, and when and how to use naloxone.
Format
Fact Sheet/Brochure
Audience
Communities
Families
Patients
Other Team Members
First Responders
Source
National Council for Mental Wellbeing
Year
Resource Type
PDF

2021-2022 Older Adult Behavioral Health (PDF - 552 kb KB)

This report, based on findings from the 2021 and 2022 National Surveys on Drug Use and Health (NSDUH) presents key substance use, mental health, and treatment indicators among adults aged 60 or older in the United States.
Format
Report/Paper/Issue Brief
Audience
Behavioral Health Providers
Families
Communities
Policymakers and Payers
States
Source
Substance Abuse and Mental Health Services Administration (SAMHSA)
Year
Resource Type
PDF

2024 National Veteran Suicide Prevention Annual Report (PDF - 9.9 MB KB)

The VA conducts the largest national analysis of Veteran suicide rates each year. Findings are made available to the public in an Annual Report in two parts���In-depth Reviews and Report Findings. The report is based on national death certificate data currently available through 2022.
Format
Report/Paper/Issue Brief
Audience
Behavioral Health Providers
Other Team Members
Communities
Source
U.S. Department of Veterans Affairs
Year
Resource Type
PDF

Campus Drug Prevention

This DEA web page includes resources to prevent drug misuse among college students, for institutions of higher education and their surrounding communities.
Format
Web Page
Audience
Schools
Communities
Source
Drug Enforcement Administration (DEA)
Year
Resource Type
Web Page

Drug Overdose Death Rates

This web page highlights statistics on deaths involving drugs commonly associated with fatal overdose from 1999-2022 collected by the National Center for Health Statistics (NCHS) at the Centers for Disease Control and Prevention.
Format
Web Page
Audience
Behavioral Health Providers
Communities
Policymakers and Payers
States
Source
National Institute on Drug Abuse (NIDA)
Year
Resource Type
Web Page

FDA recommends changes to labeling for transmucosal buprenorphine products indicated to treat opioid use disorder

This press release details the FDA's recommended changes to labeling transmucosal buprenorphine products for opioid use disorder treatment. These recommendations are motivated by concerns about misinterpretation about current labeling strategies.
Format
Web Page
Audience
Medical Providers
Behavioral Health Providers
Source
U.S. Food & Drug Administration (FDA)
Year
Resource Type
Web Page